Loading...

Caroline McCoach, MD, PhD

TitleAssistant Professor
InstitutionUniversity of California San Francisco
DepartmentMedicine
Phone415-885-3882
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Stanford University, Stanford, CAPhD2005Biochemistry
    University of Colorado, Aurora, COMD2009
    University of California, Davis, Sacramento, CAResidency/ Chief Residency2013
    University of California, Davis, Sacramento, CAResearch Fellowship2014
    University of Colorado, Aurora, COClinical Fellowship2017

    Collapse Overview 
    Collapse Overview
    Caroline McCoach is a thoracic oncologist who focuses on the treatment of patients with lung cancer as well as other thoracic malignancies. Her goal is to provide a personalized approach to treatment, based on each patient’s cancer type in combination with their individual treatment goals.

    Her primary research focus is on treatment of cancers driven by genetic mutations or alterations such as ALK, ROS1, EGFR, and others. She is also working to find treatments to prevent or delay the development of resistance to targeted therapies as well as increase the efficacy of standard targeted therapies by using rational combination treatments. She works closely with laboratory based researchers to develop new and improved treatments for lung cancer patients.


    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Blumenthal GM, Bunn PA, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JMM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol. 2018 Sep 27. PMID: 30268698.
      View in: PubMed
    2. Iams WT, Yu H, Shyr Y, Patil T, Horn L, McCoach C, Kelly K, Doebele RC, Camidge DR. First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance. Clin Lung Cancer. 2018 Aug 22. PMID: 30197261.
      View in: PubMed
    3. Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D, Tzitzilonis C, Mordec K, Marquez A, Romero J, Hsieh T, Zaman A, Olivas V, McCoach C, Blakely CM, Wang Z, Kiss G, Koltun ES, Gill AL, Singh M, Goldsmith MA, Smith JAM, Bivona TG. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat Cell Biol. 2018 Aug 13. PMID: 30104724.
      View in: PubMed
    4. McCoach CE, Le A, Gowan K, Jones KL, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC. Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer. Clin Cancer Res. 2018 Apr 10. PMID: 29636358.
      View in: PubMed
    5. McCoach CE, Blakely CM, Banks KC, Levy B, Chue BM, Raymond VM, Le A, Lee CE, Diaz J, Waqar SN, Purcell WT, Aisner DL, Davies KD, Lanman RB, Shaw AT, Doebele RC. Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer. Clin Cancer Res. 2018 Mar 29. PMID: 29599410.
      View in: PubMed
    6. McCoach CE, Bivona TG. The evolving understanding of immunoediting and the clinical impact of immune escape. J Thorac Dis. 2018 Mar; 10(3):1248-1252. PMID: 29708132.
      View in: PubMed
    7. McCoach CE, Doebele RC. The importance of the initial response to cancer treatment in predicting longer overall survival. Expert Rev Clin Pharmacol. 2018 Feb; 11(2):109-111. PMID: 29251525.
      View in: PubMed
    8. Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017 Dec; 49(12):1693-1704. PMID: 29106415.
      View in: PubMed
    9. McCoach CE, Blumenthal GM, Zhang L, Myers A, Tang S, Sridhara R, Keegan P, Pazdur R, Doebele RC, Kazandjian D. Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small cell lung cancer treated with a targeted therapy or immunotherapy. Ann Oncol. 2017 Aug 02. PMID: 29045514.
      View in: PubMed
    10. Iams WT, Yu H, Shyr Y, Patil T, Horn L, McCoach C, Kelly K, Doebele R, Camidge DR. PS01.68: Heterogeneous Clinical Syndromes Existing Within Patients with Stage IV KRAS Mutant Non-Small Cell Lung Cancer: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11(11S):S313. PMID: 27969535.
      View in: PubMed
    11. McCoach CE, Jimeno A. Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations. Drugs Today (Barc). 2016 Oct; 52(10):561-568. PMID: 27910964.
      View in: PubMed
    12. McCoach CE, Bivona TG, Blakely CM, Doebele RC. Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance. Clin Lung Cancer. 2016 Sep; 17(5):466-469. PMID: 27378174.
      View in: PubMed
    13. McCoach CE, Berge EM, Lu X, BarĂ³n AE, Camidge DR. A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non-Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry. J Thorac Oncol. 2016 Mar; 11(3):407-13. PMID: 26725180.
      View in: PubMed
    14. McCoach CE, Rogers JG, Dwyre DM, Jonas BA. Paraneoplastic Leukemoid Reaction as a Marker of Tumor Progression in Non-Small Cell Lung Cancer. Cancer Treat Commun. 2015; 4:15-18. PMID: 25932381.
      View in: PubMed
    15. McCoach CE, Doebele RC. The minority report: targeting the rare oncogenes in NSCLC. Curr Treat Options Oncol. 2014 Dec; 15(4):644-57. PMID: 25228144; PMCID: PMC4216615.
    16. Armstrong EJ, Chen DC, Westin GG, Singh S, McCoach CE, Bang H, Yeo KK, Anderson D, Amsterdam EA, Laird JR. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc. 2014 Apr 10; 3(2):e000697. PMID: 24721799; PMCID: PMC4187469.
    17. McCoach CE, Kelly K. Treatment paradigms in advanced non-small-cell lung cancer. Clin Adv Hematol Oncol. 2013 Oct; 11(10):629-39. PMID: 24518373.
      View in: PubMed
    18. McCoach CE, Aronowitz P. Fungating mass as first presentation of advanced breast cancer. J Gen Intern Med. 2014 Apr; 29(4):685. PMID: 24065379; PMCID: PMC3965749.
    19. McCoach CE, Armstrong EJ, Singh S, Javed U, Anderson D, Yeo KK, Westin GG, Hedayati N, Amsterdam EA, Laird JR. Gender-related variation in the clinical presentation and outcomes of critical limb ischemia. Vasc Med. 2013 Feb; 18(1):19-26. PMID: 23439776; PMCID: PMC3786085.
    20. Faddah DA, Ganko EW, McCoach C, Pickrell JK, Hanlon SE, Mann FG, Mieczkowska JO, Jones CD, Lieb JD, Vision TJ. Systematic identification of balanced transposition polymorphisms in Saccharomyces cerevisiae. PLoS Genet. 2009 Jun; 5(6):e1000502. PMID: 19503594; PMCID: PMC2682701.
    21. Flaig TW, Su LJ, McCoach C, Li Y, Raben D, Varella-Garcia M, Bemis LT. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. BJU Int. 2009 Jun; 103(12):1729-37. PMID: 19220256.
      View in: PubMed